146773-32-2Relevant academic research and scientific papers
COMPOUNDS AND USES THEREOF
-
Page/Page column 137; 179, (2021/10/15)
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
COMPOUNDS AND USES THEREOF
-
Page/Page column 193, (2021/08/06)
The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.
HDAC DEGRADER
-
Page/Page column 37-38; 46-47, (2021/07/31)
The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may
NG-Acyl-argininamides as NPY Y1 receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity
Weiss, Stefan,Keller, Max,Bernhardt, Günther,Buschauer, Armin,K?nig, Burkhard
experimental part, p. 6292 - 6304 (2010/10/19)
NG-Acylated argininamides, covering a broad range of lipophilicity (calculated log D values: -1.8-12.5), were synthesized and investigated for NPY Y1 receptor (Y1R) antagonism, Y 1R affinity and stability in buffer (NG-deacylation, yielding BIBP 3226). Broad structural variation of substituents was tolerated. The Ki (binding) and Kb values (Y1R antagonism) varied from low nM to one-digit μM. Most of the compounds proved to be sufficiently stable at pH 7.4 over 90 min to determine reliable pharmacological data in vitro. Exceptionally high instability was detected when a succinyl moiety was attached to the guanidine, probably, due to an intramolecular cleavage mechanism.
Novel tumor-targeted RGD peptide-camptothecin conjugates: Synthesis and biological evaluation
Dal Pozzo, Alma,Ni, Ming-Hong,Esposito, Emiliano,Dallavalle, Sabrina,Musso, Loana,Bargiotti, Alberto,Pisano, Claudio,Vesci, Loredana,Bucci, Federica,Castorina, Massimo,Fodera, Rosanna,Giannini, Giuseppe,Aulicino, Concetta,Penco, Sergio
experimental part, p. 64 - 72 (2010/04/06)
Five RGD peptide-camptothecin (CPT) conjugates were designed and synthesized with the purpose to improve the therapeutic index of this antitumoral drug family. New RGD cyclopeptides were selected on the basis of their high affinity to αv integr
TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COM OUNDS
-
Page/Page column 61, (2008/12/06)
New targeting or therapeutic compounds which can be incorporated into a composition of gas-filled microvesicles. The invention further relates to gas-filled microvesicles for diagnostic and/or therapeutic use comprising said compounds and to their method of use. The new compounds are compounds of formula M-S-T, wherein : M represents a component capable of associating with an envelope of a gas-filled microvesicle; T represents a component comprising a targeting ligand or a therapeutic agent; and S represents a component comprising at least two bissulfone groups.
